Experience
Regents of the Univ. of Cal.
Eli Lilly
Finnegan represented Eli Lilly in a landmark case brought by The Regents of University of California (UC). Two patents were at stake and both involved recombinant human insulin. UC claimed that its patents directed to DNA sequences that encode human proinsulin (a precursor to human insulin) covered Lilly's recombinant human insulin product. They argued that Lilly owed them hundreds of millions of dollars for infringing two of its patents. Finnegan succeeded in establishing that one patent was not valid and that the other patent was not infringed. On appeal, the Federal Circuit held that that the claims of the ‘525 patent, which purported to encompass human DNA, were invalid for failing to satisfy the written description of 35 U.S.C. § 112. Concerning UC's '740 patent, the Federal Circuit found that UC specifically surrendered coverage of DNA sequences during patent prosecution of the exact sort utilized by Lilly to produce its human insulin product. Therefore, the Federal Circuit held that UC could not recapture such subject matter in an infringement action.
Regents of the Univ. of Cal. v. Eli Lilly, 3:90-cv-00373, N.D. Cal., Judge Jensen
Regents of the Univ. of Cal. v. Eli Lilly, 91-ml-912, S.D. Ind., Judges Dillin, Brazil
Regents of the Univ. of Cal. v. Eli Lilly, 92-cv-00224, S.D. Ind., Judges Dillin, Godich
Eli Lilly v. Regents of the Univ. of Cal., 96-1175, Fed. Cir., Judges Newman, Lourie, Bryson
Finnegan represented Eli Lilly on first genetically engineered biologic in the United States
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Co. wins challenge to patents covering its osteoporosis drug, Evista®
Eli Lilly and Company
Sun Pharmaceutical Inds. v. Eli Lilly and Co.
Eli Lilly and Company
Eli Lilly and Co. v. Apotex Inc.
Eli Lilly and Company
ABBYY Software, Ltd., Lexmark
Eli Lilly and Company v. Sicor Pharmaceuticals, Inc.
Eli Lilly and Company
Eli Lilly & Co. v. Wockhardt Ltd.
Eli Lilly and Company
Eli Lilly and Company v. Teva Pharmaceuticals USA, Inc.
Eli Lilly and Company
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.